Elicio Therapeutics Showcases ELI-002 Progress
At the ESMO Immuno-Oncology Congress, Elicio Therapeutics, Inc. (Nasdaq: ELTX) unveiled updated results on its Phase 1 AMPLIFY-201 clinical trial. This trial focuses on ELI-002, an innovative cancer vaccine specifically targeting tumors driven by mutations in the KRAS gene. The findings indicate a substantial median recurrence-free survival (mRFS) of 16.3 months and a median overall survival (mOS) of 28.9 months among the complete study population. These results provide hope for improved treatment options for patients at heightened risk of recurrence following surgical interventions.
Insights from the ELI-002 Study
ELI-002 is an Amphiphile cancer vaccine aimed at individuals suffering from KRAS-mutant tumors, particularly those who have undergone standard treatment but still possess residual circulating tumor DNA or serum tumor biomarkers. This study included participants with mutant KRAS-driven colorectal and pancreatic cancer. The interim analysis suggests a robust correlation between the strength of the T cell response and patient survival rates, indicating the potential effectiveness of ELI-002.
Previous Research and Background
The clinical results presented at the congress by Dr. Shubham Pant from the University of Texas, MD Anderson Cancer Center, build on earlier publications, highlighting the ongoing commitment of Elicio to push forward with innovative cancer therapies. With an extensive follow-up period of 19.7 months, the data illustrates both a favorable safety profile and encouraging efficacy, reinforcing the relevance of ELI-002 in the oncology space.
Executive Insights on Elicio’s Journey
Christopher Haqq, M.D., Ph.D., Elicio’s Executive Vice President, expressed optimism regarding longer follow-ups demonstrating that patients treated with ELI-002 largely exceed expectations compared to historical data. The results showcase not just improvements in survival times, but a significant interaction between the treatment-induced T cell responses and biological markers that could signal reduced disease progression. This insight is crucial as Elicio prepares for further developments in its clinical trials.
AMPLIFY-201 and Future Directions
The AMPLIFY-201 study is pivotal, designed as a multi-center, open-label trial measuring the safety and tolerability of the ELI-002 two-peptide formulation. A total of 25 participants were enrolled, including a diverse mix of those with pancreatic ductal adenocarcinoma and colorectal cancer. The trial is particularly noteworthy as it focuses on patients who are at high risk of cancer recurrence, underscoring Elicio's strategic focus on this vulnerable patient population.
Significant Study Observations
- The updated data underscore a promising 28.9-month overall survival rate that compared favorably to historical controls.
- There was no observable Grade 3 or 4 treatment-emergent adverse events in any of the participants, indicating a strong safety profile.
- Importantly, a cohort of 13 patients with above-median T cell responses demonstrated promising survival statistics yet to reach mRFS.
About Elicio Therapeutics and ELI-002
Elicio Therapeutics, Inc. is advancing innovative immunotherapies aimed at preventing recurrence in high-prevalence cancers like KRAS-positive pancreatic and colorectal cancers. The company is working on developing effective vaccines that can be used off-the-shelf, making treatments accessible for patients who might otherwise face significant risks of relapse.
Innovations in Immunotherapy
ELI-002 represents a breakthrough in targeting prevalent KRAS mutations, which are responsible for about 25% of all solid tumors. Elicio is also conducting further studies, including ELI-002 7P, which aims to achieve an extended range of immune response by covering additional KRAS mutations. This broad approach could significantly increase the therapeutic options available to patients with various forms of KRAS-driven cancers.
Frequently Asked Questions
What is ELI-002?
ELI-002 is an investigational Ampiphile cancer vaccine developed by Elicio Therapeutics that targets KRAS mutations in patients with specific cancers.
What were the main outcomes of the Phase 1 AMPLIFY-201 study?
The study reported a median recurrence-free survival of 16.3 months and a median overall survival of 28.9 months, showcasing encouraging results for the treatment.
Who presented the results of the study?
Dr. Shubham Pant from the University of Texas, MD Anderson Cancer Center presented the findings at the ESMO Immuno-Oncology Congress.
What are the future plans for Elicio’s clinical trials?
Elicio plans to continue evaluating ELI-002 and anticipate interim analysis for the Phase 2 portion of related trials in the near future.
How does Elicio's AMP technology work?
Elicio’s AMP platform facilitates targeted delivery of immunotherapeutics directly to lymph nodes, enhancing the immune response to cancer antigens.
